Analysts Issue Forecasts for ADMA Biologics FY2024 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of ADMA Biologics in a research report issued on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings of $0.52 per share for the year, up from their prior forecast of $0.50. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.52 per share.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the company earned $0.01 earnings per share.

ADMA has been the topic of a number of other reports. HC Wainwright boosted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th.

ADMA Biologics Trading Up 2.4 %

Shares of ADMA traded up $0.39 during mid-day trading on Wednesday, hitting $16.71. 2,727,716 shares of the company's stock traded hands, compared to its average volume of 2,537,846. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.95 billion, a P/E ratio of 59.68 and a beta of 0.76. The business's 50-day moving average price is $19.29 and its 200-day moving average price is $17.23. ADMA Biologics has a 1 year low of $4.82 and a 1 year high of $23.64.

Institutional Trading of ADMA Biologics

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its position in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after buying an additional 4,945,063 shares during the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after acquiring an additional 1,442,799 shares during the period. Geode Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after purchasing an additional 137,989 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter worth approximately $61,858,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.70% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.